profit from every $100 of sales.
$0$100
BioVie
$1.19-5.56% today
-26.1% in 1 year
1-year low $0.961-year high $2.28
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What BioVie sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$17.5 million of profit last year.
SalesProfit
BioVie vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| BioVie | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads BioVie's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -27 | -45 | -32 | -18 | |
| -24 | -46 | -29 | -17 | |
| -26 | -50 | -32 | -18 | |
| -106.00 | -154.70 | -73.05 | -12.12 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 20 | 35 | 25 | 22 |
| Cash | 19 | 19 | 24 | 18 |
| Total debt | 12 | 14 | 6 | 0 |
| Total liabilities | 16 | 20 | 10 | 3 |
| 4 | 15 | 16 | 19 | |
| 0 | 0 | 0 | 1 | |
| -118.6% | -122.0% | -106.8% | -70.2% | |
| -710.6% | -327.6% | -207.1% | -92.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -19 | -40 | -28 | -19 | |
| – | – | – | – | |
| -19 | -40 | -28 | -19 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 6 | 6 | 5 | 2 |
Valuation
- –
- –
- –
- 0.6×
- –
- –
- 0.1×
- -149.1%
- -137.5%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -129.5%
- -630.2%
- -101.1%
- -113.7%
- -130.2%
- –
Growth
- –
- –
- +31.9%
- –
- +85.8%
Financial health
- 0.6×
- 0.02
- 1.7%
- -1,088.5×
- 9.97
- 9.97
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 883
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.70 | -0.73 | +4.1% |
| Feb 6, 2026 | -0.77 | -0.81 | +4.9% |
| Nov 10, 2025 | -0.98 | -0.79 | −24.1% |
| Aug 15, 2025 | -0.24 | -4.40 | +94.6% |
| May 12, 2025 | -1.50 | -3.20 | +53.1% |
| Feb 11, 2025 | -4.60 | -16.00 | +71.3% |
| Nov 13, 2024 | -7.00 | -16.00 | +56.3% |
| Sep 30, 2024 | -66.00 | -15.00 | −340.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
53No pass
Benjamin Graham
77Pass
Philip Fisher
34No pass
Peter Lynch
60Pass
Joel Greenblatt
50No pass
Charlie Munger
29No pass
Terry Smith
32No pass
Questions about BioVie
Is BioVie a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the BioVie AI analysis
What does BioVie do?
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It is in Biotechnology.
Does BioVie pay a dividend?
No. BioVie does not pay a dividend at the moment.
Is BioVie stock halal?
No. BioVie does not pass our halal screen: its cash and confirmed interest-bearing investments are 138% of its market value, at or above the 33% limit. How we check
How has BioVie stock done over the past year?
Down 26.1% over the past twelve months, to $1.19. It traded between $0.96 and $2.28 and is 47.8% below its high.
Who are BioVie's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with BioVie's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.